Aaron Umasoye Udogadi1* , Okonko IO2 and Frank-Peterside N2
Aim:However, advances in Human Immunodeficiency Virus (HIV) biology, pharmacology and clinical medicine made it possible for Human Immunodeficiency Virus (HIV)-infected persons to live longer; they also experience long-term adverse side effects and toxicity due to treatment and ageassociated co-morbidity.
Materials and methods:The study population included experienced patients (≥ 3 months). All eligible samples that met inclusion criteria: Confirmed positive by Human Immunodeficiency Virus HIV-1/HIV-2 at time of enrolment via same study draw or historically from medical record or at least 1.2 mL leftover EDTA plasma or serum sample from p24 Ag positive patients. Human Immunodeficiency Virus (HIV) (1+2) quick test strip (Determinee, Alere Co, LTD, Japan) for screening analysis; while Stat-Pak (Chembio Diagnostic Systems, Inc., New York, NY, USA). Immunochromatographic assay for the detection of antibodies to Hepatitis C, Hepatitis B Surface Antigen while Enzyme-Linked Immunosorbent Assay (ELISA) technique was used to detect Hepatitis E.
Results:This study result showed that Hepatitis B surface antigen (HBsAg)-HIV co-infection was 2% and HCV-HIV coinfection being 1%. At the same time, there was 0% coinfection with the Hepatitis E virus (HEV).
Conclusion: However, the research reaffirms our understanding of the coinfection of HIV with Hepatitis B surface antigen (HBsAg), Hepatitis C Virus (HCV) among people living with Human Immunodeficiency Virus (HIV) in Rivers State.
